🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today was a ROUGH day for alcohol-associated hepatitis therapeutic pipeline: Canakinumab (IL-1β mAb) phase 2 (ISAIAH) didn't meet primary outcome shorturl.at/Xvmbs Surrozen SZN-043 stops development after phase 1b shorturl.at/eU457 Dire need for new AH therapy!

It’s almost here…still a few seats left for all the procrastinators out there See you tomorrow bright and early ALD_ALLY #NYC

Excellent talk on Early Detection Strategies for ALD by Marina Serper, MD, MS at ALD_ALLY The denominator of pts with ALD also include those not engaged in care

Using implementation science to improve ALD care by Shari Rogal ALD_ALLY meeting

Optimizing treatment of AUD in ALD by Akhil Shenoy at ALD_ALLY meeting

High impact studies in ALD in the past year -moving the field forward by Juan Pablo (JP) Arab, MD  at ALD_ALLY VCU Stravitz-Sanyal Institute for Liver Disease

Alexandre Louvet discusses clinical trial design in AH and ALD ALD_ALLY

Minimum unit pricing and Alcohol policies to improve health by Sumeet Asrani at ALD_ALLY

Potential MetALD pharmacotherapies talk by Rohit Loomba at ALD_ALLY UC San Diego Health

Incredible panel of world-class experts discussing MetALD at ALD_ALLY Mazen Noureddin, MD, MHSc Rohit Loomba Marina Serper, MD, MS Hannes Hagstrom Sumeet Asrani

Thanks to our All-Star panel of speakers at ALD_ALLY. A great day of insights and actionable initiatives.

The attendees at ALD_ALLY were the real stars ALD_ALLY. Great discussions and interactions all day. Thank you What a group!

Patient advocate Jenn Jones Sober Livers leading a panel on the Future on ALD care at ALD_ALLY Thank you for sharing your voice!

Congratulations Giuseppe Cullaro on this eye-opening study! Columbia Medicine NYC Transplant Hepatology

En route to San Diego for #DDW2025 with some AASLD swag Excited to represent AASLD at a few sessions on MetALD and AH. See you there!

New pet-peeve unlocked: a conference on steatotic liver disease (SLD) with no mention of alcohol 😬

Dismayed seeing this ALERT when visiting the great NIAAA News alcohol treatment navigator website that our team uses daily to connect patients to alcohol care. Federal funding cuts hurt patients, especially the most vulnerable.

Great synopsis Hanna! 1 unresolved question is what proportion of pts with MetALD have co-occurring alcohol use disorder? The answer will inform a lot: definition validity, appropriate alcohol treatment, clinical trial design, etc. My guess: it's high w/ most MetALD being ALD.